MX2022014019A - Moduladores de akt3 y métodos para su uso. - Google Patents

Moduladores de akt3 y métodos para su uso.

Info

Publication number
MX2022014019A
MX2022014019A MX2022014019A MX2022014019A MX2022014019A MX 2022014019 A MX2022014019 A MX 2022014019A MX 2022014019 A MX2022014019 A MX 2022014019A MX 2022014019 A MX2022014019 A MX 2022014019A MX 2022014019 A MX2022014019 A MX 2022014019A
Authority
MX
Mexico
Prior art keywords
akt3
methods
modulators
disclosed
various diseases
Prior art date
Application number
MX2022014019A
Other languages
English (en)
Spanish (es)
Inventor
Samir Khleif
Mikayel Mkrtchyan
Original Assignee
Georgiamune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Llc filed Critical Georgiamune Llc
Publication of MX2022014019A publication Critical patent/MX2022014019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplitude Modulation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022014019A 2020-05-08 2021-05-07 Moduladores de akt3 y métodos para su uso. MX2022014019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022014019A true MX2022014019A (es) 2023-02-16

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014019A MX2022014019A (es) 2020-05-08 2021-05-07 Moduladores de akt3 y métodos para su uso.

Country Status (11)

Country Link
US (1) US20230181563A1 (he)
EP (1) EP4146196A4 (he)
JP (1) JP2023525758A (he)
KR (1) KR20230019109A (he)
CN (1) CN115956078A (he)
AU (1) AU2021269065A1 (he)
BR (1) BR112022022327A2 (he)
CA (1) CA3182675A1 (he)
IL (1) IL297596A (he)
MX (1) MX2022014019A (he)
WO (1) WO2021226510A2 (he)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096129A2 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
KR20090089854A (ko) * 2006-10-12 2009-08-24 수퍼젠, 인크. Ｄｎａ 메틸화 조절을 위한 퀴놀린 유도체
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US9707278B2 (en) * 2014-04-17 2017-07-18 Augusta University Research Institute, Inc. Methods of modulating immune responses by modifying Akt3 bioactivity
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
IL272909B2 (he) * 2017-09-07 2024-01-01 Univ Res Inst Inc Augusta מפעיל akt3 ספציפי ושימושים בו

Also Published As

Publication number Publication date
EP4146196A2 (en) 2023-03-15
US20230181563A1 (en) 2023-06-15
AU2021269065A1 (en) 2022-12-15
BR112022022327A2 (pt) 2023-01-03
IL297596A (he) 2022-12-01
KR20230019109A (ko) 2023-02-07
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
CN115956078A (zh) 2023-04-11
CA3182675A1 (en) 2021-11-11
WO2021226510A2 (en) 2021-11-11
WO2021226510A9 (en) 2022-01-13
EP4146196A4 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
MY197427A (en) Combination therapy for the treatment or prevention of tumours
MX2024000054A (es) Tratamiento de tumores positivos a gen 3 de activacion de linfocitos (lag-3).
EP4085919A3 (en) Compositions and methods to treat cancer
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR112018007304A2 (pt) terapia de combinação para tratamento de malignidades
MX2022008305A (es) Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
BR112021020247A2 (pt) Composições e métodos para melhorar a saúde da pele e para o tratamento e prevenção de doenças, distúrbios e afecções associadas a micróbios patogênicos
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
NZ582556A (en) Pharmaceutical composition for treating wounds and related methods
MX2021013318A (es) Terapias de combinacion que comprenden inhibidores de apremilast y tyk2.
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2023015236A (es) Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2023013052A (es) Inhibidores de la via de la cinasa jano 1 (jak1) para el tratamiento del prurigo nodularis.
CO2020009731A2 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos
MX2022002069A (es) Inhibidores de enzimas.
MX2023006651A (es) Tratamiento de la hemofilia con fitusirán.
MX2023005501A (es) Combinaciones de inhibidores de metap2 e inhibidores de cdk4/6 para el tratamiento de cáncer.
MX2022014019A (es) Moduladores de akt3 y métodos para su uso.
MX2022004259A (es) Inhibidores de mek para el tratamiento de infecciones por hantavirus.
MX2021016106A (es) Composición que modula el efecto de la neurotoxina botulínica.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.